Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma

Mezigdomide is in clinical development for the treatment of relapsed or refractory multiple myeloma (RRMM) in combination with carfilzomib and dexamethasone after 1 or more prior treatments. Multiple myeloma is a type of blood cancer that is characterised by an abundance of abnormal immune cells, known as plasma cells, in the bone marrow. Symptoms include persistent bone pain, raised calcium levels in the blood, unusual bleeding and kidney problems. RRMM can be defined as multiple myeloma that is non-responsive to therapy, disease that progresses within 60 days of the last administration of therapy, or previously treated multiple myeloma that has progressed after prior therapy and requires new therapy. Outcomes for patients with disease progression is poor, therefore there is a need to develop new treatment options for RRMM.